S. Qi

New, potent, and selective peptidic oxytocin receptor agonists.

P. Rivière, R. Laporte, R. Galyean, 2014, Journal of medicinal chemistry.

Kisspeptin treatment induces gonadotropic responses and rescues ovulation in a subset of preclinical models and women with polycystic ovary syndrome

T. Kohout, M. J. Vazquez, R. Anderson, 2019, Human reproduction.

Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome

P. Rivière, D. Hargrove, Karthik Srinivasan, 2020, The Journal of Pharmacology and Experimental Therapeutics.

Synthesis and Pharmacological Characterization of Novel Glucagon-like Peptide-2 (GLP-2) Analogues with Low Systemic Clearance.

P. Rivière, Yung-Chih Wang, J. J. Dwyer, 2016, Journal of medicinal chemistry.

Discovery of Potent, Selective, and Short-Acting Peptidic V2 Receptor Agonists.

P. Rivière, D. Hargrove, J. Kraus, 2019, Journal of medicinal chemistry.

Pharmacological Characterization of FE 202158, a Novel, Potent, Selective, and Short-Acting Peptidic Vasopressin V1a Receptor Full Agonist for the Treatment of Vasodilatory Hypotension

P. Rivière, J. Dykert, R. Laporte, 2011, Journal of Pharmacology and Experimental Therapeutics.

Selective and non-selective OT receptor agonists induce different locomotor behaviors in male rats via central OT receptors and peripheral V1a receptors

Karthik Srinivasan, H. Wiśniewska, K. Wiśniewski, 2018, Neuropeptides.

Unlike arginine vasopressin, the selective V1a receptor agonist FE 202158 does not cause procoagulant effects by releasing von Willebrand factor*

L. Traber, D. Traber, P. Rivière, 2012, Critical care medicine.